Patient-Centric Clinical Trial Team Science Awards - LOI required

Sponsor Deadline: 

Jan 18, 2023

Letter of Intent Deadline: 

Oct 5, 2022

Sponsor: 

Melanoma Research Alliance

UI Contact: 

At present, there are many early-stage, phase I clinical trials investigating treatment options whereby multiple different treatments for a particular tumor type can yield similar efficacy results. One method to differentiate between available treatment options – and to be more efficient in the development of new treatment options – is to use Health Related Quality of Life or Patient Reported Outcomes to assist with clinical decision-making. While these endpoints are usually captured in randomized phase 3 studies, HRQOL and PROs can be beneficial at all phases of clinical development. During phase 1 clinical trials, the impact of therapeutic agents and combination therapies on toxicity is unknown and traditional endpoints may not fully capture this information. However, this is an area where HRQOL and PRO may add value and can be used to capture symptom quantification or functional improvement or decline. In breast cancer, HRQOL and PROs are used to predict risk for serious adverse events, revolutionizing the way in which clinical trials are implemented. As a result, this collaboration seeks to support early phase clinical trials where patient reported outcomes are used in addition to clinical endpoints to identify and better explore treatment options that best meet the needs of patients with melanoma.

Categories: